GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Current Accrued Expense

Incanthera (AQSE:INC) Current Accrued Expense : £0.00 Mil (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Incanthera Current Accrued Expense?

Incanthera's Current Accrued Expense for the quarter that ended in Sep. 2023 was £0.00 Mil.


Incanthera Current Accrued Expense Historical Data

The historical data trend for Incanthera's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Current Accrued Expense Chart

Incanthera Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Current Accrued Expense
- - - -

Incanthera Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Current Accrued Expense Get a 7-Day Free Trial - - - - -

Incanthera Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Incanthera Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Incanthera's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Incanthera (AQSE:INC) Business Description

Traded in Other Exchanges
N/A
Address
76 King Street, Manchester, GBR, M2 4NH
Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines